Can we, should we, eradicate the meningococcus?

被引:11
|
作者
Maiden, Martin C. J. [1 ]
Frosch, Matthias [2 ]
机构
[1] Univ Oxford, Dept Zool, Oxford OX1 3PS, England
[2] Univ Wurzburg, Inst Fuer Hyg & Mikrobiol, D-97080 Wurzburg, Germany
基金
英国惠康基金;
关键词
Neisseria meningitidis; Vaccines; Epidemiology; Population biology; NEISSERIA-MENINGITIDIS; CARRIED MENINGOCOCCI; CONJUGATE VACCINE; SEROGROUP; DISEASE; IMMUNITY; IMMUNOGENICITY; DIVERSITY; EVOLUTION; VIRULENCE;
D O I
10.1016/j.vaccine.2011.12.068
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The eradication of infectious agents is an attractive means of disease control that, to date, has been achieved for only one human pathogen, the smallpox virus. The introduction of vaccines against Neisseria meningitidis into immunisation schedules, and particularly the conjugate polysaccharide vaccines which can interrupt transmission, raises the question of whether disease caused by this obligate human bacterium can be controlled, eliminated, or even eradicated. The limited number of meningococcal serogroups, lack of an animal reservoir, and importance of meningococcal disease are considerations in favour of eradication; however, the commensal nature of most infections, the high diversity of meningococcal populations, and the lack of comprehensive vaccines are all factors that suggest that this is not feasible. Indeed, any such attempt might be harmful by perturbing the human microbiome and its interaction with the immune system. On balance, the control and possible elimination of disease caused by particular disease-associated meningococcal genotypes is a more achievable and worthwhile goal. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:B52 / B56
页数:5
相关论文
共 50 条
  • [21] Why we should be looking for longitudinal patterns in biodiversity
    Proches, Serban
    Watkeys, Michael K. K.
    Ramsay, Lisa F. F.
    Cowling, Richard M. M.
    FRONTIERS IN ECOLOGY AND EVOLUTION, 2023, 11
  • [22] Glomeromycotina: what is a species and why should we care?
    Bruns, Thomas D.
    Corradi, Nicolas
    Redecker, Dirk
    Taylor, John W.
    Opik, Maarja
    NEW PHYTOLOGIST, 2018, 220 (04) : 963 - 967
  • [23] Should we vaccinate during an active rheumatic disease?
    Bijl, Marc
    Westra, Johanna
    Mancuso, Silvia
    Bearzi, Pietro
    Giacomelli, Roberto
    Conti, Fabrizio
    AUTOIMMUNITY REVIEWS, 2024, 23 (01)
  • [24] Beyond killing Can we find new ways to manage infection?
    Vale, Pedro F.
    McNally, Luke
    Doeschl-Wilson, Andrea
    King, Kayla C.
    Popat, Roman
    Domingo-Sananes, Maria R.
    Allen, Judith E.
    Soares, Miguel P.
    Kummerli, Rolf
    EVOLUTION MEDICINE AND PUBLIC HEALTH, 2016, (01) : 148 - 157
  • [25] Avian flu pandemic: Can we prevent it?
    Iwami, Shingo
    Takeuchi, Yasuhiro
    Liu, Xianning
    JOURNAL OF THEORETICAL BIOLOGY, 2009, 257 (01) : 181 - 190
  • [26] Can We Prevent Congenital Infection by Cytomegalovirus?
    Plotkin, Stanley A.
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (10) : 1705 - 1707
  • [27] Body composition in disease: what can we measure and how can we measure it?
    Van Loan, MD
    ACTA DIABETOLOGICA, 2003, 40 (Suppl 1) : S154 - S157
  • [28] Should We Measure Quality by the Dose?
    Cannon, Christopher P.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (19) : 1802 - 1803
  • [29] Should We Advocate Maternal Immunization?
    Boonyaratanakornkit, Jim
    Chu, Helen Y.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2019, 38 (06) : S28 - S32
  • [30] Body composition in disease: what can we measure and how can we measure it?
    M. D. Van Loan
    Acta Diabetologica, 2003, 40 : s154 - s157